Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS019 in advanced solid tumors
NCT05508373Phase 1Unknown
- Sponsor
- Suzhou Kebo Ruijun Biosciences
- Start
- Mar 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of JS019 in solid tumor (advanced stage) (4 arms), sponsored by Suzhou Kebo Ruijun Biosciences. Primary endpoints: Incidence of DLT, severity of adverse events (AEs) and serious adverse events (SAEs) at 2 years and Maximum Tolerated Dose (MTD) or Optimal Biological Effect Dose (OBD) and Phase II study recommended dose (RP2D) at 2 years. Status: unknown.
02
Drugs
JS019
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05508373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05508373.